Abstract: The present disclosure provides a spinal cord stimulation (SCS) system. The system includes at least one SCS lead including a lead body, at least one distal electrode located at a distal end of the lead body, the at least one distal electrode configured to apply electrical stimulation to a stimulation target of a patient, and a pain reduction assembly coupled to the lead body and configured to reduce post-operation pain at an incision site associated with implantation of the at least one SCS lead. The system further includes a pulse generator coupled to the at least one SCS lead and configured to control electrical stimulation delivered to the patient via the at least one SCS lead.

Abstract: An ablation catheter (10) includes a body (12) having a distal end (16), a hollow tip (22) attached to the distal end and an ultrasound transducer assembly positioned within the hollow tip and mounted to rotate about a longitudinal axis of the catheter body. The hollow tip includes an acoustically transparent shell, which allows acoustic energy to pass to and from the ultrasound transducer assembly, and an electrically-conductive coating on its exterior surface, which allows ablating energy to be delivered to an adjacent tissue. A plurality of ribs extend inwardly from an inner surface of the shell. A system (100) incorporating the ablation catheter and methods of using the same to ablate, image and/or monitor tissue are also disclosed.

Abstract: The present disclosure provides a spinal cord stimulation (SCS) system. The system includes at least one SCS lead including a lead body, at least one distal electrode located at a distal end of the lead body, the at least one distal electrode configured to apply electrical stimulation to a stimulation target of a patient, and a pain reduction assembly coupled to the lead body and configured to reduce post-operation pain at an incision site associated with implantation of the at least one SCS lead. The system further includes a pulse generator coupled to the at least one SCS lead and configured to control electrical stimulation delivered to the patient via the at least one SCS lead.

Abstract: Diastolic function is monitored within a patient based on dynamic cardiogenic impedance as measured by a pacemaker or other implantable medical device. In one example, the device uses ventricular cardiogenic impedance values to detect E-wave parameters representative of passive filling of the ventricles. Atrial cardiogenic impedance values are used to detect A-wave parameters representative of active filling of the ventricles. Diastolic function is then assessed or evaluated based on the E-wave and A-wave parameters. Various functions of the implantable device are then controlled based on the assessment of diastolic function, such as by adjusting atrioventricular delay parameters to improve diastolic function. In some examples, the detection of E- and A-wave parameters is achieved by aligning impedance signals to atrial activation, and separately to ventricular activation, during asynchronous VOO pacing or while artificially inducing a 2:1 block.

Abstract: Diastolic function is monitored within a patient based on dynamic cardiogenic impedance as measured by a pacemaker or other implantable medical device. In one example, the device uses ventricular cardiogenic impedance values to detect E-wave parameters representative of passive filling of the ventricles. Atrial cardiogenic impedance values are used to detect A-wave parameters representative of active filling of the ventricles. Diastolic function is then assessed or evaluated based on the E-wave and A-wave parameters. Various functions of the implantable device are then controlled based on the assessment of diastolic function, such as by adjusting atrioventricular delay parameters to improve diastolic function. In some examples, the detection of E- and A-wave parameters is achieved by aligning impedance signals to atrial activation, and separately to ventricular activation, during asynchronous VOO pacing or while artificially inducing a 2:1 block.

Abstract: A system and method for current steering a neurostimulation signal is provided. The system and method provide a lead coupled to an implantable pulse generator (IPG). The lead may include a plurality of electrodes. The lead may be configured to be implanted at a target position proximate to tissue of interest. The system and method program the IPG to deliver at least a first pulse train to a first electrode and a second pulse train to a second electrode. The first and second pulse trains are interleaved with one another such that the first and second pulse trains form an activation current density distribution steered to overlay the tissue of interest.

Abstract: Methods and systems are provided to deliver a neural stimulation therapy to treat apnea episodes. The methods and systems detect a respiratory pattern of a patient and identify a type associated with the respiratory pattern. A sleep stage is detected that the patient is experiencing and the method and system identify when the sleep stage warrants therapy. When the respiratory pattern corresponds to an apnea episode (AE) and the sleep stage warrants therapy, the methods and systems deliver an apnea episode terminating neuro-stimulation (AET-NS) therapy configured to terminate the AE. A type of AE therapy that is delivered may be based on the sleep stage that was detected. The methods and systems may determine whether the AET-NS therapy successfully terminated the AE, and, if not, adjust the AET-NS therapy and deliver a new AET-NS therapy.

Abstract: Methods and systems are provided to deliver a neural stimulation therapy to treat apnea episodes. The methods and systems detect a respiratory pattern of a patient and identify a type associated with the respiratory pattern. A sleep stage is detected that the patient is experiencing and the method and system identify when the sleep stage warrants therapy. When the respiratory pattern corresponds to an apnea episode (AE) and the sleep stage warrants therapy, the methods and systems deliver an apnea episode terminating neuro-stimulation (AET-NS) therapy configured to terminate the AE. A type of AE therapy that is delivered may be based on the sleep stage that was detected. The methods and systems may determine whether the AET-NS therapy successfully terminated the AE, and, if not, adjust the AET-NS therapy and deliver a new AET-NS therapy.

Abstract: A method for performing deep brain stimulation (DBS) therapy may include determining a location of a target area of a brain, forming a burr hole through a skull of a patient based on the location the target area, positioning one or more reference members on or within the brain through the burr hole, and acquiring at least one image of the brain having the one or more reference members with at least one imaging sub-system.

Abstract: A method and system are provided for characterizing chamber specific function. The method and system comprise collecting cardiac signals associated with asynchronous timing between first and second chambers of the heart; collecting dynamic impedance (DI) data along a chamber-specific function (CSF) vector to form a DI data set, the DI data set collected during a collection window that is temporally aligned based on a timing feature of interest (FOI); repeating the collection operations over multiple cardiac cycles (CC) to obtain an ensemble of DI data sets; and combining the ensemble of DI data sets to form a composite DI data set that is coupled to a chamber functional mechanic of interest (FMOI) associated with the first chamber and decoupled from functional mechanics associated with the second chamber; and analyzing the composite DI data set to obtain a CSF indicator associated with the chamber FMOI of the first chamber.

Abstract: A method and system are provided for characterizing cardiac function. The method and system comprise collecting cardiac signals associated with electrical or mechanical behavior of a heart over at least one cardiac cycle; identifying a timing feature of interest (FOI) from the cardiac signals; collecting dynamic impedance (DI) data over at least one cardiac cycle (CC), designated by the timing FOI, along at least one of i) a venous return (VR) vector or ii) a right ventricular function (RVF) vector; and analyzing at least one morphologic characteristic from the DI data based on at least one of i) a VR-DI correlation metric to obtain a VR indicator associated with the CC or ii) a RVF-DI correlation metric to obtain a RVF indicator associated with CC.

Abstract: A method for performing deep brain stimulation (DBS) therapy may include determining a location of a target area of a brain, forming a burr hole through a skull of a patient based on the location the target area, positioning one or more reference members on or within the brain through the burr hole, and acquiring at least one image of the brain having the one or more reference members with at least one imaging sub-system.

Abstract: An ablation catheter includes an elongated body having a proximal end and a distal end. At least one ablation element is disposed on the body between the proximal end and the distal end and configured to ablate renal tissue to control hypertension. At least one localization sensor is disposed on the body and configured to interact with a magnetic field. The at least one localization sensor aids in determining an appropriate target tissue for ablation.

Abstract: Methods and systems are provided to deliver a neural stimulation therapy to treat apnea episodes. The methods and systems detect a respiratory pattern of a patient and identify a type associated with the respiratory pattern. A sleep stage is detected that the patient is experiencing and the method and system identify when the sleep stage warrants therapy. When the respiratory pattern corresponds to an apnea episode (AE) and the sleep stage warrants therapy, the methods and systems deliver an apnea episode terminating neuro-stimulation (AET-NS) therapy configured to terminate the AE. A type of AE therapy that is delivered may be based on the sleep stage that was detected. The methods and systems may determine whether the AET-NS therapy successfully terminated the AE, and, if not, adjust the AET-NS therapy and deliver a new AET-NS therapy.

Abstract: A neurostimulation lead including an elongated lead body having a distal end and a proximal base. The lead body may have an elastic property such that the lead body is capable of flexing between different geometries. The lead may also include electrodes positioned along the lead body. The lead body may be configured to be straightened into a substantially linear geometry for delivering the lead body into an epidural space and may be biased such that the lead body is configured to have a wave-like geometry when disposed within the epidural space. The lead body may form first and second lateral segments that are joined by a corresponding linking portion when in the wave-like geometry.

Abstract: An implantable medical device, comprised of at least one lead configured to be located proximate to a heart, the at least one lead including electrodes, at least a portion of the electrodes configured to sense cardiac activity. A therapy module configured to control delivery of pacing pulses in accordance with a therapy timing and based on the cardiac sensed activity sensed. Cardiac impedance (CI) sensor circuitry configured to be coupled to at least a first combination of the electrodes to sense cardiac impedance (CI), the CI sensor circuitry generating an impedance data stream associated with a corresponding CI sensing vector.

Abstract: Techniques are provided for detecting and distinguishing stroke and cardiac ischemia based on electrocardiac signals. In one example, the device senses atrial and ventricular signals within the patient along a set of unipolar sensing vectors and identifies certain morphological features within the signals such as PR intervals, ST intervals, QT intervals, T-waves, etc. The device detects changes, if any, within the morphological features such as significant shifts in ST interval elevation or an inversion in T-wave shape, which are indicative of stroke or cardiac ischemia. By selectively comparing changes detected along different unipolar sensing vectors, the device distinguishes or discriminates stroke from cardiac ischemia within the patient. The discrimination may be corroborated using various physiological and hemodynamic parameters. In some examples, the device further identifies the location of the ischemia within the heart.

Abstract: A method and system are provided for characterizing chamber specific function. The method and system comprise collecting cardiac signals associated with asynchronous timing between first and second chambers of the heart; collecting dynamic impedance (DI) data along a chamber-specific function (CSF) vector to form a DI data set, the DI data set collected during a collection window that is temporally aligned based on a timing feature of interest (FOI); repeating the collection operations over multiple cardiac cycles (CC) to obtain an ensemble of DI data sets; and combining the ensemble of DI data sets to form a composite DI data set that is coupled to a chamber functional mechanic of interest (FMOI) associated with the first chamber and decoupled from functional mechanics associated with the second chamber; and analyzing the composite DI data set to obtain a CSF indicator associated with the chamber FMOI of the first chamber.

Abstract: A method and system are provided for determining fluid status with a central venous system of a heart. Dynamic impedance (DI) data and static impedance (SI) data are collected over multiple cardiac cycles (CC) for a persistent time period of interest (POI). The DI and SI data are collected along a central venous (CV) vector that extends through a superior vena cava (SVC). The DI and SI data are analyzed to obtain DI long-term variation (LTV) information and SI LTV information, respectively, and to detect whether the DI LTV information and the SI LTV information include decreasing persistent trends in the DI and SI data. When decreasing persistent trends are detected in the DI and SI data, an overload output is generated to indicate that the heart is experiencing a volume overload state. The DI and SI data represent a surrogate for central venous pressure.

Abstract: Diastolic function is monitored within a patient based on dynamic cardiogenic impedance as measured by a pacemaker or other implantable medical device. In one example, the device uses ventricular cardiogenic impedance values to detect E-wave parameters representative of passive filling of the ventricles. Atrial cardiogenic impedance values are used to detect A-wave parameters representative of active filling of the ventricles. Diastolic function is then assessed or evaluated based on the E-wave and A-wave parameters. Various functions of the implantable device are then controlled based on the assessment of diastolic function, such as by adjusting atrioventricular delay parameters to improve diastolic function. In some examples, the detection of E- and A-wave parameters is achieved by aligning impedance signals to atrial activation, and separately to ventricular activation, during asynchronous VOO pacing or while artificially inducing a 2:1 block.